Tackling Tuberculosis in Indonesia with Shorter, More Effective, Cost-Efficient Therapy

A study from Indonesia shows the six-month, all-oral BPaL regimen for drug-resistant TB reduced treatment costs by 67% and increased treatment success by 18%, making it significantly more efficient cost effective. Backed by strong government leadership and a new partnership with TB Alliance, Indonesia is positioning itself as a global leader in advancing innovative, patient-friendly TB care.